Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer-Reference-Cited by-同舟云学术

Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

Published:2010-04-12 Issue:17 Volume:107 Page:7875-7880
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proc Natl Acad Sci USA

Author:

Matsuzaki Junko,Gnjatic Sacha,Mhawech-Fauceglia Paulette,Beck Amy,Miller Austin,Tsuji Takemasa,Eppolito Cheryl,Qian Feng,Lele Shashikant,Shrikant Protul,Old Lloyd J.,Odunsi Kunle

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference24 articles.

1. The Immunobiology of Cancer Immunosurveillance and Immunoediting

2. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

3. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

4. Vascular Leukocytes: a Population with Angiogenic and Immunossuppressive Properties Highly Represented in Ovarian Cancer

5. Odunsi K (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63:6076â6083.

Cited by 741 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors in infectious disease;Immunological Reviews;2024-09-09

2. LAG-3 in Cancer Immunotherapy: A Comprehensive Review;International Journal of Advanced Research in Science, Communication and Technology;2024-09-05

3. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

4. Baseline sLAG-3 levels in Caucasian and African-American breast cancer patients;Breast Cancer Research and Treatment;2024-09-04

5. T cell exhaustion and senescence for ovarian cancer immunotherapy;Seminars in Cancer Biology;2024-09